# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-337950
Filing Date
2026-08-06
Accepted
2026-08-06 16:05:51
Documents
69
Period of Report
2026-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | ctmx-20260630.htm iXBRL | 10-Q | 2956448
2 | EX-10.3 REGENERON AMENDMENT 3 | ctmx-ex10_3.htm | EX-10.3 | 32423
3 | EX-10.4 REGENERON AMENDMENT 4 | ctmx-ex10_4.htm | EX-10.4 | 26056
4 | EX-31.1 | ctmx-ex31_1.htm | EX-31.1 | 20149
5 | EX-31.2 | ctmx-ex31_2.htm | EX-31.2 | 20256
6 | EX-32.1 | ctmx-ex32_1.htm | EX-32.1 | 13216
7 | EX-32.2 | ctmx-ex32_2.htm | EX-32.2 | 13137
| Complete submission text file | 0001193125-26-337950.txt |  | 9860272

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | ctmx-20260630.xsd | EX-101.SCH | 1097951
73 | EXTRACTED XBRL INSTANCE DOCUMENT | ctmx-20260630_htm.xml | XML | 1763736

Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37587 | Film No.: 261248874
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)